ESMO 23: Amgen's Lumakras/Vectibix Combo Clinches Colorectal Cancer Win
Executive Summary
The higher dose of Amgen's Lumakras combined with Vectibix has demonstrated significant superiority in progression-free survival over investigator's choice of therapy in KRAS G12C-mutated metastatic colorectal cancer but the discussant at the combo's ESMO presentation wants to see overall survival data before getting too excited.
You may also be interested in...
ESMO 23: Analysts Keep Faith In Revolution’s Multi-RAS Drug Despite Investor Fright
Revolution Medicines is aiming to go beyond Amgen and Mirati’s first-generation drugs with a multi-RAS targeting therapy - and despite a market sell-off after ESMO, analysts think the company think it is still on track.
BMS Looks To Expand Its Oncology Reach With Mirati Buyout
Bristol Myers Squibb will add Krazati to its oncology portfolio by buying Mirati Therapeutics in a deal worth up to $5.8bn, but needs to smooth out the so-far bumpy progress of the KRAS-targeting agent and achieve success in immunotherapy combinations.
US FDA In No Hurry To Withdraw Amgen’s Lumakras Despite Negative Adcomm Vote On Confirmatory Trial Results
ODAC votes 10-2 that the progression-free survival data in CodeBreaK 200 cannot be reliably interpreted due to various study conduct issues; agency assures the committee that it is not currently proposing withdrawal and that multiple regulatory pathways are available for sotorasib, one of two KRAS G12C inhibitors on the market under accelerated approval.